{"disease":{"id":"biliary-tract-cancer-btc","name":"biliary tract cancer btc"},"drugs":{"marketed":[{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."},{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06975917","title":"Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ankara University","has_results":false},{"nct_id":"NCT07454486","title":"TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT07169916","title":"Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06622057","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":195,"lead_sponsor_name":"InnoPharmax Inc.","has_results":false},{"nct_id":"NCT07197554","title":"A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":171,"lead_sponsor_name":"SEED Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07206355","title":"In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03314935","title":"A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07326137","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","phase":"","overall_status":"RECRUITING","enrollment_count":103,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07159204","title":"Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07099794","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07351591","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT06919848","title":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06611345","title":"A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","has_results":false},{"nct_id":"NCT03790111","title":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"TerSera Therapeutics LLC","has_results":true},{"nct_id":"NCT07466238","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06903273","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT07398339","title":"Cosiporfin Sodium for Injection Photodynamic Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Guangsheng Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04004234","title":"A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}